Cargando…

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors

Tyrosine kinase receptors promote the growth and differentiation of normal breast and malignant human breast cancer cells, known as ERBB receptors. Various ERBB receptors are EGFR/ErbB1 and ErbB2/neu, which get over expressed in different solid tumors that activate upon binding of ligand to the extr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonar, Priyanka, Shaikh, Karimunnisa, Ballav, Sangeeta, Basu, Soumya, Harer, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Biomedical Informatics 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465783/ https://www.ncbi.nlm.nih.gov/pubmed/37654845 http://dx.doi.org/10.6026/97320630018974

Ejemplares similares

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3
por: Sergina, Natalia V., et al.
Publicado: (2007)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
por: Conlon, Neil T., et al.
Publicado: (2021)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
por: Yang, Xue, et al.
Publicado: (2020)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
por: Yang, Lu, et al.
Publicado: (2022)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2(+ )breast cancer
por: Cortés-Funes, H, et al.
Publicado: (2009)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
por: Griffin, Nathan, et al.
Publicado: (2020)

Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
por: Li, Dong-Dong, et al.
Publicado: (2013)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion
por: Aceto, Nicola, et al.
Publicado: (2012)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors
por: Lin, Chun-Han, et al.
Publicado: (2015)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression
por: Khan, Sheema, et al.
Publicado: (2016)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
por: Romaniello, Donatella, et al.
Publicado: (2020)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
por: Guti, Eliza, et al.
Publicado: (2022)

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
por: Hinow, Peter, et al.
Publicado: (2007)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
por: Kankia, Ibrahim H., et al.
Publicado: (2021)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
por: Diaz, Roque, et al.
Publicado: (2010)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
por: Han, Han, et al.
Publicado: (2021)

Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis
por: Yu, Yushuai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qvo466b79hsiotf0m22qr6a89j